Enliven Therapeutics Q2 2023 net loss $16.7M; cash $277.9M; Phase 1 data expected 2024

Enliven Therapeutics, Inc.

2023-Q2 EPS reported -$1.05

Net loss of $16.7M for Q2 2023, compared to $8.9M in Q2 2022.
Cash, cash equivalents and marketable securities total $277.9M as of June 30, 2023.
R&D expenses $15.2M vs $7.9M; G&A expenses $5.0M vs $1.1M (year-over-year).
Phase 1 trials for ELVN-001 (CML) and ELVN-002 (HER2+) advancing with initial safety/efficacy data expected in 2024.
Third program product candidate selected; more details to be disclosed in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Enliven Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income $16.7 million.

Period: the second quarter ended June 30, 2023
Net income: $16.7 million
Result: reported results

Exact text from the filing

Enliven reported a net loss of $16.7 million for the second quarter of 2023, compared to a net loss of $8.9 million for the second quarter of 2022.

View on SEC.gov

Browse all earnings releases →

Enliven Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-041322

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.